Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Grabs Ibis’ T5000 Biosensor System For Infectious Disease Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Abbott will focus on developing molecular diagnostics for hospital-acquired infections using Ibis Biosciences' T5000 biosensor system after acquiring the business for $215 million

You may also be interested in...



Push For Rapid Diagnostics, Protective Equipment Amid Flu Outbreak

Government health officials and industry are scrambling to identify and release diagnostics technology that can quickly identify patients stricken with the hybrid flu virus sweeping the globe, while demand for respirators and other personal protective equipment is rising

Push For Rapid Diagnostics, Protective Equipment Amid Flu Outbreak

Respirators and other personal protective equipment for health workers treating flu sufferers would be part of a $1.5 billion appropriation President Obama called on Congress to provide through FY 09 supplemental appropriations.

Push For Rapid Diagnostics, Protective Equipment Amid Flu Outbreak

Government health officials and industry are scrambling to identify and release diagnostics technology that can quickly identify patients stricken with the hybrid flu virus sweeping the globe, while demand for respirators and other personal protective equipment is rising

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel